Clinical and biological features of t(4;14) multiple myeloma: a prospective study

References

• Kuehl WM, Bergsagel PL. Early genetic events provide the basis for a clinical classification of multiple myeloma. Hematology Am Soc Hematol Educ Program 2005:346–352.
   PubMedGoogle Scholar
• Avet-Loiseau H, Facon T, Grosbois B, etal. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002;99:2185–2191.
   PubMed Web of Science ®Google Scholar
• Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998;92:3025–3034.
   PubMed Web of Science ®Google Scholar
• Chandesris MO, Soulier J, Labaume S, etal. Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma. Br J Haematol 2007;136:609–614.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Debes-Marun CS, Picken EB, etal. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 2003;102:2562–2567.
   PubMed Web of Science ®Google Scholar
• Keats JJ, Reiman T, Maxwell CA, etal. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003;101:1520–1529.
   PubMed Web of Science ®Google Scholar
• Chang H, Sloan S, Li D, etal. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004;125:64–68.
   PubMed Web of Science ®Google Scholar
• Cavo M, Terragna C, Renzulli M, etal. Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. J Clin Oncol 2006;24:e4–e5.
   PubMed Web of Science ®Google Scholar
• Moreau P, Attal M, Garban F, etal. Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia 2007;21:2020–2024.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Bailey RJ, Ahmann GJ, etal. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002;100:1417–1424.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Facon T, Daviet A, etal. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res 1999;59:4546–4550.
   PubMed Web of Science ®Google Scholar
• Durie BG, Harousseau JL, Miguel JS, etal. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–1473.
   PubMed Web of Science ®Google Scholar
• Landgren O, Kyle RA, Pfeiffer RM, etal. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009;113:5412–5417.
   PubMed Web of Science ®Google Scholar
• Van Wier S, Ahmann G, Kimberly J, etal. The t(4;14) is present in patients with early stage plasma cell proliferative disorders including MGUS and smoldering multiple myeloma (SMM). Blood 2005;106(Suppl. 1): Abstract 1545.
   Google Scholar
• Avet-Loiseau H, Leleu X, Roussel M, etal. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010;28:4630–4634.
   PubMed Web of Science ®Google Scholar
• Tosi P, Terragna C, Testoni N, etal. Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. Eur J Haematol 2008;80:31–36.
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Facon T, etal. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495–2502.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009;114:3139–3146.
   Google Scholar
• Lahuerta JJ, Mateos MV, Martinez-Lopez J, etal. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008;26:5775–5782.
   PubMed Web of Science ®Google Scholar
• Pineda-Roman M, Zangari M, Haessler J, etal. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol 2008;140:625–634.
   PubMed Web of Science ®Google Scholar
• Kapoor P, Kumar S, Fonseca R, etal. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2009;114:518–521.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, etal. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906–917.
   PubMed Web of Science ®Google Scholar
• Rosinol L, Oriol A, Mateos MV, etal. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol 2007;25:4452–4458.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Palumbo A, Richardson P, etal. Superior outcomes associated with complete response: analysis of the phase III VISTA study of bortezomib plus melphalan–prednisone versus melphalan–prednisone. Blood 2008;112(Suppl. 1): Abstract 2778.
   PubMed Web of Science ®Google Scholar
• Jaksic W, Trudel S, Chang H, etal. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol 2005;23:7069–7073.
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Richardson PG, Rajkumar SV, etal. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol 2008;143:46–53.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster M, etal. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110:3557–3560.
   Web of Science ®Google Scholar
• Sagaster V, Ludwig H, Kaufmann H, etal. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 2007;21:164–168.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Soulier J, Fermand JP, etal. Impact of chromosomal abnormalities del(13), t(4;14), and del(17p) and prior treatment on outcomes in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2008;112(Suppl. 1): Abstract 3685.
   Google Scholar
• Reece D, Song KW, Fu T, etal. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 2009;114:522–525.
   PubMed Web of Science ®Google Scholar
• Chng WJ, Jacobus S, Fonseca R. Do beta2 microglobulin levels affect survival of newly diagnosed myeloma patients with translocation t(4;14) or 17p13 deletion treated with conventional chemotherapy? Leukemia 2008;22:1080–1081.
   PubMed Web of Science ®Google Scholar
• Xin X, Abrams TJ, Hollenbach PW, etal. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice. Clin Cancer Res 2006;12:4908–4915.
   PubMed Web of Science ®Google Scholar
• Trudel S, Li ZH, Wei E, etal. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005;105:2941–2948.
   PubMed Web of Science ®Google Scholar
• Arnulf B, Ghez D, Leblond V, etal. FGFR3 tyrosine kinase inhibitor AB1010 as treatment of t(4;14) multiple myeloma. Blood 2007;110(Suppl. 1): Abstract 413.
   Google Scholar